COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review

Bonuomo, Valentina; Ferrarini, Isacco; Dell'Eva, Michele; Sbisà, Eugenio; Krampera, Mauro; Visco, Carlo

doi:10.5501/wjv.v10.i6.312

Cited by 29 publications

(39 citation statements)

References 71 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of COVID-19 was found to be more frequent in acute leukemias (29%), followed by non-Hodgkin’s lymphoma (27%) and Hodgkin’s lymphoma (18%) [ 24 ]. Furthermore, an increase in mortality has been reported in myeloid malignancies (MDS/AML/MPN) than lymphoid neoplasms (NHL/CLL/ALL/MM/HL) (43% vs. 35%) [ 25 , 26 ], which is similar to that seen in our study population. The majority of our study patients were on active treatment and reported a mortality rate of 19.6%, in contrast to 10% among patients on surveillance.…”

Section: Discussionsupporting

confidence: 90%

“Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan”

et al. 2022

View full text Add to dashboard Cite

Purpose COVID-19 infection resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to spread across the globe in early 2020. Patients with hematologic malignancies are supposed to have an increased risk of mortality from coronavirus disease of 2019 (COVID-19) infection. From Pakistan, we report the analysis of the outcome and interaction between patient demographics and tumor subtype and COVID-19 infection and hematological malignancy. Patients and methods This multicenter, retrospective study included adult patients with a history of histologically proven hematological malignancies who were tested positive for COVID-19 via PCR presented at the oncology department of 5 tertiary care hospitals in Pakistan from February to August 2020. A patient with any known hematological malignancy who was positive for COVID-19 on RT-PCR, was included in the study. Chi-square test and Cox-regression hazard regression model was applied considering p ≤ 0.05 significant. Results A total of 107 patients with hematological malignancies were diagnosed with COVID-19, out of which 82 (76.64%) were alive, and 25 (23.36%) were dead. The significant hematological malignancy was B-cell Lymphoma in dead 4 (16.00%) and alive group 21 (25.61%), respectively. The majority of the patients in both the dead and alive group were on active treatment for hematological malignancy while they came positive for COVID-19 [21 (84.00%) & 48 (58.54%) p 0.020]. All patients in the dead group were admitted to the hospital 25 (100.00%), and among these, 14 (56.00%) were admitted in ICU with a median 11 (6–16.5) number of days. Among those who had contact exposure, the hazard of survival or death in patients with hematological malignancies and COVID-19 positive was 2.18 (CI: 1.90–4.44) times and 3.10 (CI: 2.73–4.60) times in patients with travel history compared to no exposure history (p 0.001). Conclusion Taken together, this data supports the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality resulting from COVID-19 infection.

show abstract

Section: Discussionsupporting

confidence: 90%

“Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan”

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Lymphoma patients are often immunosuppressed by their active disease per se, and lymphodepleting therapies including anti-CD20 monoclonal antibodies, chemotherapy, with targeted agents also leading to an additional immunosuppressive effect. 20 The speed and degree of humoral and cellular immune recovery following prolonged immunosuppression following therapy interruption is unclear. The impact of different therapeutic approaches in patients with COVID-19 remains poorly defined, but active chemotherapy appears to be associated with increased risk of death in cancer patients with COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry

et al. 2022

Self Cite

View full text Add to dashboard Cite

Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL patients with COVID-19 infection were collected, aiming to identify risk factors for mortality from COVID-19. In our retrospective, multicenter, international study, we collected data from 63 MCL patients with a median age of 64 years (range, 44–84) in 9 countries with evidence of a COVID-19 infection between February 2020 and October 2021. The overall mortality rate was high (44.4%), especially in hospitalized patients (61%) and in patients with need for intensive care unit care (94%). Patients receiving rituximab had significantly poorer survival than patients not receiving rituximab (P = 0.04). Our data highlight the importance of prevention strategies and underline the need for effective vaccination in this vulnerable cohort.

show abstract

“…Prior studies showed high rates of COVID-19 severity in patients with B-lymphoid malignancies, but no increase in COVID-19 severity or mortality associated with treatment of B-lymphoid malignancies. However, these studies were smaller than the current study and did not compare outcomes with untreated control populations (11,14,23,24). This is the largest study of patients specifically with B-lymphoid malignancies and COVID-19 to date, with a cohort of 995 of such patients.…”

Section: Discussionmentioning

confidence: 78%

Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Rubinstein

Bhutani

Lynch

et al. 2022

Blood Cancer Discovery

View full text Add to dashboard Cite

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anti-cancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared to control populations of patients with non-B-lymphoid hematologic malignancies. Among patients with B-lymphoid malignancies, those who received anti-cancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared to patients with B-lymphoid malignancies off therapy, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.

show abstract

COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review

Cited by 29 publications

References 71 publications

“Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan”

“Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan”

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry

Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Contact Info

Product

Resources

About